The goal of this clinical study is to find out if cadonilimab or ateganosine plus cadonilimab is effective and safe in treating resectable hepatocellular carcinoma (HCC).
Diagnosis of HCC confirmed by histology or according to the American Association for the Study of Liver Disease (AASLD) criteria
HCC that is amenable to R0 resection with curative intent as determined by treating surgical/medical oncologists in consultation with the principal investigator. Subject must be a suitable candidate for surgery based on evaluations by the treating surgeon/oncologist.
Measurable disease according to RECIST 1.1
No prior anti-PD (Programmed death)-1/L1 therapies for any indication
Presence of extrahepatic extension of disease
Prior locoregional therapy to target lesions is not allowed. History of curative locoregional therapy is allowed provided the following are met: 1) previously treated tumor is not viable without evidence of residual disease for at least 12 months, and 2) patient has not received local therapy in the past 12 months.
Known fibrolamellar HCC or combined HCC-cholangiocarcinoma histology
History of hepatic encephalopathy
University of Texas Southwestern Medical Center
Lead sponsor
Maia Biotechnology
Collaborator
National Cancer Institute (NCI)
Collaborator